Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

The Potential Impact of Connexin 43 Expression on Bcl-2 Protein Level and Taxane Sensitivity in Head and Neck Cancers-In Vitro Studies.

Gurbi B, Brauswetter D, Varga A, Gyulavári P, Pénzes K, Murányi J, Zámbó V, Birtalan E, Krenács T, Becker DL, Csala M, Vályi-Nagy I, Peták I, Dános K.

Cancers (Basel). 2019 Nov 22;11(12). pii: E1848. doi: 10.3390/cancers11121848.

2.

Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.

Murányi J, Varga A, Gyulavári P, Pénzes K, Németh CE, Csala M, Pethő L, Csámpai A, Halmos G, Peták I, Vályi-Nagy I.

Int J Mol Sci. 2019 Nov 8;20(22). pii: E5590. doi: 10.3390/ijms20225590.

3.

NRF2-regulated cell cycle arrest at early stage of oxidative stress response mechanism.

Márton M, Tihanyi N, Gyulavári P, Bánhegyi G, Kapuy O.

PLoS One. 2018 Nov 28;13(11):e0207949. doi: 10.1371/journal.pone.0207949. eCollection 2018.

4.

Discovery and optimization of novel benzothiophene-3-carboxamides as highly potent inhibitors of Aurora kinases A and B.

Gyulavári P, Szokol B, Szabadkai I, Brauswetter D, Bánhegyi P, Varga A, Markó P, Boros S, Illyés E, Szántai-Kis C, Krekó M, Czudor Z, Őrfi L.

Bioorg Med Chem Lett. 2018 Oct 15;28(19):3265-3270. doi: 10.1016/j.bmcl.2018.05.064. Epub 2018 Jun 1.

PMID:
30143423
5.

Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.

Szabadkai I, Torka R, Garamvölgyi R, Baska F, Gyulavári P, Boros S, Illyés E, Choidas A, Ullrich A, Őrfi L.

J Med Chem. 2018 Jul 26;61(14):6277-6292. doi: 10.1021/acs.jmedchem.8b00672. Epub 2018 Jul 9.

PMID:
29928803
6.

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues.

Murányi J, Varga A, Gurbi B, Gyulavári P, Mező G, Vántus T.

J Vis Exp. 2017 Mar 21;(121). doi: 10.3791/55529.

7.

Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells.

Murányi J, Gyulavári P, Varga A, Bökönyi G, Tanai H, Vántus T, Pap D, Ludányi K, Mező G, Kéri G.

J Pept Sci. 2016 Aug;22(8):552-60. doi: 10.1002/psc.2904.

PMID:
27443981
8.

Correction: Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro.

Varga A, Gyulavári P, Greff Z, Futosi K, Németh T, Simon-Szabó L, Kerekes K, Szántai-Kis C, Brauswetter D, Kokas M, Borbély G, Erdei A, Mócsai A, Kéri G, Vántus T.

PLoS One. 2015 Dec 16;10(12):e0144792. doi: 10.1371/journal.pone.0144792. eCollection 2015. No abstract available.

9.

Targeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitro.

Varga A, Gyulavári P, Greff Z, Futosi K, Németh T, Simon-Szabó L, Kerekes K, Szántai-Kis C, Brauswetter D, Kokas M, Borbély G, Erdei A, Mócsai A, Kéri G, Vántus T.

PLoS One. 2015 Apr 14;10(4):e0124234. doi: 10.1371/journal.pone.0124234. eCollection 2015. Erratum in: PLoS One. 2015;10(12):e0144792.

10.

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.

Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Orfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Orfi L, Vántus T, Kéri G.

ACS Med Chem Lett. 2014 Jan 30;5(4):298-303. doi: 10.1021/ml4003309. eCollection 2014 Apr 10.

11.

[Development and biochemical characterization of EGFR/c-Met dual inhibitors].

Szokol B, Gyulavári P, Baska F, Ibolya K, Greff Z, Szántai KC, Zoltán O, Peták I, Axel U, Vantus T, Kéri G, Orfi L.

Acta Pharm Hung. 2013;83(4):121-33. Hungarian.

PMID:
24575658

Supplemental Content

Loading ...
Support Center